The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
VIM-2–producing Multidrug-Resistant Pseudomonas aeruginosa ST175 Clone, Spain
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“‘High-risk’ clones13, such as ST235, ST111 and ST175 (refs. 144–146), are particularly concerning owing to their worldwide prevalence and the dissemination of resistance genes, including carbapenemases.”
From Pseudomonas aeruginosa: ecology, evolution, pathogenesis and antimicrobial susceptibility (2025) · cites this paper as [146]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Research works printed but not linked: 35
- Aloush, 2006, Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact., Antimicrob Agents Chemother, 50, 43, 10.1128/AAC.50.1.43-48.2006 · DOI · Paper page
- Livermore, 2002, Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?, Clin Infect Dis, 34, 634, 10.1086/338782 · DOI · Paper page
- Queenan, 2007, Carbapenemases: the versatile β-lactamases., Clin Microbiol Rev, 20, 440, 10.1128/CMR.00001-07 · DOI · Paper page
- Cornaglia, 2011, Metallo-β-lactamases: a last frontier for β-lactams?, Lancet Infect Dis, 11, 381, 10.1016/S1473-3099(11)70056-1 · DOI · Paper page
- Walsh, 2005, Metallo-beta-lactamases: the quiet before the storm?, Clin Microbiol Rev, 18, 306, 10.1128/CMR.18.2.306-325.2005 · DOI · Paper page
- Poirel, 2000, Characterization of VIM-2, a carbapenem-hydrolyzing metallo β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France., Antimicrob Agents Chemother, 44, 891, 10.1128/AAC.44.4.891-897.2000 · DOI · Paper page
- Riccio, 2001, In70 of plasmid pAX22, a blaVIM-1-containing integron carrying a new aminoglycoside phosphotransferase gene cassette., Antimicrob Agents Chemother, 45, 1249, 10.1128/AAC.45.4.1249-1253.2001 · doi:10.1128/aac.45.4.1249-1253.2001
- Obritsch, 2004, National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002., Antimicrob Agents Chemother, 48, 4606, 10.1128/AAC.48.12.4606-4610.2004 · DOI · Paper page
- Leibovici, 1998, The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection., J Intern Med, 244, 379, 10.1046/j.1365-2796.1998.00379.x · DOI · Paper page
- Gutiérrez, 2007, Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals., Antimicrob Agents Chemother, 51, 4329, 10.1128/AAC.00810-07 · doi:10.1128/aac.00810-07
- Rossolini, 2008, First countrywide survey of acquired metallo-β-lactamase in gram-negative pathogens in Italy., Antimicrob Agents Chemother, 52, 4023, 10.1128/AAC.00707-08 · doi:10.1128/aac.00707-08
- Juan, 2008, Characterization of the new metallo-β-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain., Antimicrob Agents Chemother, 52, 3589, 10.1128/AAC.00465-08 · DOI
- Peña, 2007, Nosocomial spread of Pseudomonas aeruginosa producing the metallo-β-lactamase VIM-2 in a Spanish hospital: clinical and epidemiological implications., Clin Microbiol Infect, 13, 1026, 10.1111/j.1469-0691.2007.01784.x · doi:10.1111/j.1469-0691.2007.01784.x
- Riera, 2011, Pseudomonas aeruginosa carbapenem resistance mechanism in Spain: impact on the activity of imipenem, meropenem and doripenem., J Antimicrob Chemother, 66, 2022, 10.1093/jac/dkr232 · DOI · Paper page
- Viedma, 2009, Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum b-lactamases GES-1 and GES-5 in Spain., Antimicrob Agents Chemother, 53, 4930, 10.1128/AAC.00900-09 · DOI
- Cantón, 2000, Evaluation of the Wider system, a new computer-assisted image-processing device for bacterial identification and susceptibility testing., J Clin Microbiol, 38, 1339, 10.1128/JCM.38.4.1339-1346.2000 · doi:10.1128/jcm.38.4.1339-1346.2000
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, vol. 26, no. 3. 16th informational supplement. M100–S16. Wayne (PA): The Institute; 2006.
- Tenover, 1995, Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing., J Clin Microbiol, 33, 2233, 10.1128/JCM.33.9.2233-2239.1995 · DOI · Paper page
- Curran, 2004, Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa., J Clin Microbiol, 42, 5644, 10.1128/JCM.42.12.5644-5649.2004 · DOI · Paper page
- Pournaras, 2003, Hospital outbreak of multiple clones of Pseudomonas aeruginosa carrying the unrelated metallo-beta-lactamase gene variants blaVIM-2 and blaVIM-4., J Antimicrob Chemother, 51, 1409, 10.1093/jac/dkg239 · doi:10.1093/jac/dkg239
- Gibb, 2002, Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new bla(IMP) allele, bla(IMP-7)., Antimicrob Agents Chemother, 46, 255, 10.1128/AAC.46.1.255-258.2002 · DOI · Paper page
- Crespo, 2004, Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia., J Clin Microbiol, 42, 5094, 10.1128/JCM.42.11.5094-5101.2004 · DOI
- Ryoo, 2009, Outbreak by meropenem-resistant Pseudomonas aeruginosa producing IMP-6 metallo-beta-lactamase in a Korean hospital., Diagn Microbiol Infect Dis, 63, 115, 10.1016/j.diagmicrobio.2008.08.019 · DOI
- Deplano, 2007, Emergence and dissemination of multidrug resistant clones of Pseudomonas aeruginosa producing VIM-2 metallo-beta-lactamase in Belgium., Euro Surveill, 12
- Lolans, 2005, First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States., Antimicrob Agents Chemother, 49, 3538, 10.1128/AAC.49.8.3538-3540.2005 · DOI
- Castanheira, 2009, Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, −5, −6, and −11 and the newly characterized VIM-18)., Antimicrob Agents Chemother, 53, 1225, 10.1128/AAC.01011-08 · DOI
- García-Castillo, 2011, Wide dispersion of ST175 clone despite high genetic diversity of carbapenem-nonsusceptible Pseudomonas aeruginosa clinical strains in 16 Spanish hospitals., J Clin Microbiol, 49, 2905, 10.1128/JCM.00753-11 · DOI
- Cholley, 2011, Most multidrug-resistant Pseudomonas aeruginosa isolates from hospitals in eastern France belong to a few clonal types., J Clin Microbiol, 49, 2578, 10.1128/JCM.00102-11 · DOI
- Nemec, 2010, Multidrug-resistant epidemic clones among bloodstream isolates of Pseudomonas aeruginosa in the Czech Republic., Res Microbiol, 161, 234, 10.1016/j.resmic.2010.02.002 · doi:10.1016/j.resmic.2010.02.002
- Libisch, 2009, Identification of two multidrug-resistant Pseudomonas aeruginosa clonal lineages with a countrywide distribution in Hungary., Curr Microbiol, 58, 111, 10.1007/s00284-008-9285-7 · DOI
- Elias, 2010, Nosocomial outbreak of VIM-2 metallo-β-lactamase producing Pseudomonas aeruginosa associated with retrograde urography., Clin Microbiol Infect, 16, 1494, 10.1111/j.1469-0691.2010.03146.x · DOI
- Pagani, 2005, Nosocomial outbreak caused by multidrug-resistant Pseudomonas aeruginosa producing IMP-13 metallo-beta-lactamase., J Clin Microbiol, 43, 3824, 10.1128/JCM.43.8.3824-3828.2005 · DOI
- Duljasz, 2009, First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria., Antimicrob Agents Chemother, 53, 2221, 10.1128/AAC.01573-08 · doi:10.1128/aac.01573-08
- Acosta, 2011, Multidrug-resistant Acinetobacter baumannii harboring OXA-24 carbapenemase, Spain., Emerg Infect Dis, 17, 1064, 10.3201/eid1706.091866 · doi:10.3201/eid1706.091866
- Tam, 2008, Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint., Clin Infect Dis, 46, 862, 10.1086/528712 · DOI
Cited by
The Resistome of Pseudomonas aeruginosa in Relationship to Phenotypic Susceptibility
Kos, V. N., Déraspe, M., McLaughlin, R. E., Whiteaker, J. D., Roy, P. H., Alm, R. A., Corbeil, J., & Gardner, H. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03954-14 · Cited by 264
Pseudomonas aeruginosa: ecology, evolution, pathogenesis and antimicrobial susceptibility
Letizia, M., Diggle, S. P., & Whiteley, M. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01193-8 · Cited by 231
Mobile Carbapenemase Genes in Pseudomonas aeruginosa
Yoon, E.-J., & Jeong, S. H. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.614058 · Cited by 221
Metadata
- Authors
- Viedma, E., Juan, C., Villa, J., Barrado, L., Orellana, M. Á., Sanz, F., Otero, J. R., Oliver, A., & Chaves, F.
- Venue
- Emerging Infectious Diseases
- Published
- 2012-08
- Volume
- 18
- Issue
- 8
- ISSN
- 1080-6040
- 1080-6059
- Cited by
- 62
- References
- 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: VIM-2–producing Multidrug-Resistant Pseudomonas aeruginosa ST175 Clone, Spain. https://app.cochat.ai/papers/10.3201/eid1808.111234
- The paper
- Viedma, E., Juan, C., Villa, J., Barrado, L., Orellana, M. Á., Sanz, F., Otero, J. R., Oliver, A., & Chaves, F. (2012). VIM-2–producing Multidrug-Resistant Pseudomonas aeruginosa ST175 Clone, Spain. Emerging Infectious Diseases. https://doi.org/10.3201/eid1808.111234
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.